1 Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine is a piperazine derivative with the general properties of H 1 - blocking drugs but is used as an anti-emetic in a variety of clinical situations including druginduced and motion sickness, vertigo, post-operative vomiting and radiation sickness. The mechanism of the anti-emetic effect is unclear. Cyclizine also possesses anticholinergic activity but does not have marked sedative effects. Pharmacokinetics H1-blockers are well absorbed from the GI tract. Following oral administration effects develop within 30 minutes, are maximal within 1-2 hours and last, for cyclizine, for 4-6 hours. Cyclizine is extensively N-demethylated to norcyclizine which is widely distributed throughout the tissues and has a plasma half-life of less than 1 day. Indications Nausicalm is indicated for the prevention and treatment of nausea and vomiting including motion sickness, nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period and radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. Nausicalm may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance. Dosage and Administration Adults and children over 12 Years: One tablet up to three times daily. Children 6 12 Years: Half a tablet up to three times daily. Children under 6 Years: Not recommended. Use in the Elderly: There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate. Contraindications Nausicalm should not be given to individuals with known hypersensitivity to cyclizine.
2 Warnings and Precautions As with other anticholinergic agents, cyclizine should be used with caution and appropriate monitoring in patients with glaucoma, obstructive disease of the gastrointestinal tract and in males with possible prostatic hypertrophy. Cyclizine should be used with caution in patients with severe heart failure. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure. There have been no specific studies in hepatic and/or renal dysfunction. Cyclizine was not mutagenic in a full Ames test, including use of S9-microsomes. No long-term studies have been conducted in animals to determine whether cyclizine has a potential for carcinogenesis. Pregnancy and Lactation [Category A] Some animal studies are interpreted as indicating that cyclizine may be teratogenic. In a study involving prolonged administration of cyclizine to male and female rats there was no evidence of impaired fertility after continuous treatment for 90 to 100 days. There is no experience of the effect of cyclizine on human fertility. In the absence of any definitive human data, the use of cyclizine in pregnancy is not advised. It is not known whether cyclizine or its metabolites are excreted in human milk. Effects on Ability to Drive and Use Machines Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine. Patients should not drive or operate machinery until they have determined their own response. Although there are no data available, patients should be cautioned that cyclizine may have additive effects with alcohol and other central nervous system depressants, e.g. hypnotics and tranquillisers. Adverse Effects Eye disorders: oculogyric crisis General disorders and administration site conditions: asthenia. Injection site reactions including vein tracking, erythema, pain, thrombophlebitis and blisters. A sensation of heaviness, chills and pruritus have been reported rarely.
3 Hepatobiliary disorders: hepatic dysfunction, hypersensitivity hepatitis, cholestatic jaundice and cholestatic hepatitis. Musculoskeletal and connective tissue disorders: twitching, muscle spasms Nervous System Disorders: somnolence, headache, dystonia, dyskinesia, extrapyramindal motor disturbances, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia Psychiatric disorders: disorientation, agitation Respiratory, thoracic and mediastinal disorders: bronchospasm, apnoea Skin and subcutaneous tissue disorders: urticaria, drug rash, angioedema Vascular Disorders: hypertension, hypotension Urticaria, drug rash, drowsiness, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded. Other Central Nervous System effects which have been recorded rarely include dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness and transient speech disorders. Cholestatic jaundice has occurred in association with cyclizine. Single case reports have been documented of fixed drug eruption, generalised chorea, hypersensitivity hepatitis and agranulocytosis. Interactions Cyclizine may have additive effects with alcohol and other central nervous system depressants e.g. hypnotics, tranquillisers. Cyclizine enhances the soporific effect of pethidine. Because of its anticholinergic activity cyclizine may enhance the side-effects of other anticholinergic drugs. Overdosage Symptoms: Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system. Peripheral anticholinergic symptoms include, dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, inco-ordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression. An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg. Treatment: In the management of acute overdosage with cyclizine, gastric lavage and supportive measures for respiration and circulation should be performed if necessary. Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy.
4 Pharmaceutical Precautions Store below 25 C. Store in a safe place out of the reach of children. Medicine Classification Pharmacist Only Medicine Package Quantities Blister pack of 10 tablets Further Information List of excipients: potato starch, lactose, gum acacia and magnesium stearate. Name and Address AFT Pharmaceuticals Ltd P O Box Takapuna AUCKLAND Telephone: (09) Facsimile: (09) Date of Preparation April 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST. POMALYST (pomalidomide)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XOLAIR safely and effectively. See full prescribing information for XOLAIR. XOLAIR (omalizumab) for
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYBELLA safely and effectively. See full prescribing information for KYBELLA. KYBELLA (deoxycholic
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TANZEUM safely and effectively. See full prescribing information for TANZEUM. TANZEUM (albiglutide)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA (pembrolizumab)
THE COLLEGE OF FAMILY PHYSICIANS OF CANADA LE COLLÈGE DES MÉDECINS DE FAMILLE DU CANADA Authorizing Dried Cannabis for Chronic Pain or Anxiety preliminary guidance September 2014 This guidance document
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An educational aid to improve care and safety with opioid therapy 2010 Update What is New in this Revised Guideline New data, including
Gel-One" P080020/A0l14 SEIKAGAKU CORPORATION Patient Information Gel-One Be sure to read the following important information carefully. This information does not take the place of your doctor's advice.
May 6, 2015 Data from 2014 Quarter 2 NEW SAFETY PERSPECTIVES Zolpidem (AMBIEN) safety profile shows widespread unsafe use Adverse event signals for canagliflozin (INVOKANA), a new diabetes medication 20,632
Surgical outpatients Hospital admission Theatre and recovery Discharge Primary care referral Pre-operative assessment Post-operative care Management of adults with diabetes undergoing surgery and elective
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services R Evaluation and Management Services Guide November 2014 / ICN: 006764 PREFACE This guide is offered as a reference tool
Emergency treatment of anaphylactic reactions Guidelines for healthcare providers Working Group of the Resuscitation Council (UK) January 2008 Annotated with links to NICE guidance July 2012 Review Date:
A Behind the Headlines report June 2011 Supplements Who needs them? Foreword Millions of us take vitamins and dietary supplements hoping to achieve good health, ease our illnesses or defy ageing. Recent
Attitudes and Beliefs About the Use of Over-the-Counter Medicines: A Dose of Reality A National Survey of Consumers and Health Professionals Prepared for: National Council on Patient Information and Education
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
SPECIAL ARTICLE Anesthesiology 2002; 96:1004 17 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists
The Journal of Pain, Vol 10, No 2 (February), 2009: pp 113-130 Available online at www.sciencedirect.com Opioid Treatment Guidelines Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 The recommendations contained herein were adopted as policy by the Executive Committee of the Federation of State
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
Abuse-Deterrent Opioids Evaluation and Labeling Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Clinical Medical
Preface This report, which updates handbooks issued in 969, 973, and 979, reviews the epidemiology of botulism in the United States since 899, the problems of clinical and laboratory diagnosis, and the
THE TREATMENT OF DIARRHOEA A manual for physicians and other senior health workers World Health Organization Department of Child and Adolescent Health and Development THE TREATMENT OF DIARRHOEA A manual
OSHA 3142-12R 2004 Lead in Construction Employers are responsible for providing a safe and healthy workplace for their employees. OSHA s role is to promote the safety and health of America s working men
Recognizing Drug Use in Adolescents A Quick Guide for Caregivers and Adults 1 Recognizing Drug Use in Adolescents A Quick Guide for Caregivers and Adults Concerned caregivers and adults play an important
section 1 Promoting Recovery from First Episode Psychosis i Talking to Clients ii section 1 Promoting Recovery from First Episode Psychosis A Guide for Families Lisa Martens, msw, rsw, and Sabrina Baker,